PITTSBURGH, April 12 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application (ANDA) for Fexofenadine Hydrochloride Tablets, 30mg, 60mg and 180mg. Fexofenadine Hydrochloride Tablets are the AB-rated generic equivalent of Aventis Pharmaceuticals' Allegra(R) Tablets, which had annual U.S. sales of approximately $1.4 billion as of December 31, 2005, according to IMS Health
About Mylan Laboratories
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc. that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.
For more information about Mylan, visit http://www.mylan.com.
Mylan Laboratories Inc.CONTACT: Media, Patrick Fitzgerald, or Investors, Kris King, both of MylanLaboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com//
